

Chris Garabedian

“A Biopharma Career from A to X: Lessons Learned from Abbott to Xontogeny (and Gilead, Celgene and Sarepta along the way)”

Chris Garabedian founded Xontogeny, LLC, a Boston based company, to support multiple promising technologies from early development through clinical proof of concept. He also formed a partnership with Perceptive Advisors, LLC in 2017 to establish the firm’s venture fund strategy. Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of the company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group.



Wednesday, April 18, 2018 from 5:30 to 8:00 pm
Greehey Children’s Cancer Research Institute, (GCCRI)

Sponsorship Provided By

BRACEWELL

[REGISTER HERE](#)